Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

September 21, 2020September 21, 2020

Enrollment Completed in Phase 2 Trial of Oral On-demand HAE Therapy KVD900

News

The Phase 2 clinical trial testing KalVista Pharmaceuticals‘ oral investigational therapy KVD900 as an on-demand treatment for hereditary angioedema (HAE) attacks has completed enrollment, the company announced. Results from the trial are expected by year’s ... Read more

May 13, 2020May 13, 2020

Costs Unsustainable for New Angioedema Preventive Therapies in US, Real-world Data Show

News

Costs are unsustainable for preventive treatment of hereditary angioedema (HAE) attacks with approved therapies Takhzyro or Haegarda, according to an analysis of six-month real-world data performed by the pharmacy benefit manager ... Read more

March 9, 2020March 9, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

February 25, 2020April 8, 2020

FDA Agrees to Review Berotralstat as Preventive Treatment for HAE Attacks

News

The U.S. Food and Drug Administration (FDA) agreed to review BioCryst Pharmaceuticals‘ application requesting approval of oral berotralstat as a once-daily treatment to prevent swelling attacks in people with ... Read more

February 11, 2020February 11, 2020

Preventative Therapy for HAE Attacks, Haegarda, Now Available in Quebec

News

Haegarda, a C1-INH replacement medication by CSL Behring, is now available in the Canadian province of Quebec for the preventative treatment of swelling attacks in adults and adolescents with hereditary ... Read more

February 4, 2020February 26, 2020

BioCryst Seeks Berotralstat Approval in Japan for Prevention of HAE Attacks

News

BioCryst Pharmaceuticals has submitted an application to the Japanese regulatory authority asking that oral berotralstat (BCX7353) be approved for the prevention of swelling attacks in people with hereditary angioedema ... Read more

January 30, 2020February 14, 2020

EMA Approves New Production Facility for Ruconest, Pharming’s Treatment for Acute HAE Attacks

News

The European Medicines Agency (EMA) has approved a type II variation for a new facility to produce Ruconest (conestat alfa), Pharming’s lead therapy for acute attacks in hereditary angioedema (HAE). ... Read more

January 13, 2020February 6, 2020

Update Coming on Phase 2 Trial of KalVista’s Oral HAE Therapy KVD900

News

Results of the Phase 2 clinical trial testing KalVista Pharmaceuticals‘ oral investigational therapy KVD900 as an on-demand treatment for hereditary angioedema (HAE) attacks will be announced by August. The ... Read more

June 13, 2019June 20, 2019

Takhzyro Induces Rapid Resolution of Hereditary Angioedema Attacks, New Data Analysis Shows

News

Treatment with Takhzyro (lanadelumab) effectively reduces the number of attacks in patients with hereditary angioedema even in early phases of treatment, new analysis of data from the Phase 3 HELP ... Read more

August 2, 2018

BioCryst’s BCX7353 Prevents Attacks in HAE Patients, Phase 2 Trial Shows

News

Daily treatment with BCX7353, an investigative oral inhibitor of plasma kallikrein, reduces the rate of attacks in hereditary angioedema (HAE) patients by more than 70%, a Phase 2 study shows. Also, more patients ... Read more

Pin It on Pinterest